Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Grenda A, Jarosz B, Krawczyk P, et al. Discrepancies between ALK protein disruption and occurrence of ALK generearrangement in polish NSCLC patients. J Thorac Dis. 2018;10(8):4994–4999.
   PubMed Web of Science ®Google Scholar
• Guo M, Zuo D, Zhang J, et al. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: synthesisand biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives. Eur J Med Chem. 2018;158:322–323.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Seto T, Takenoyama M, et al. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev. 2015;34(4):797–805.
   PubMed Web of Science ®Google Scholar
• Griesinger F, Roeper J, Pöttgen C, et al. Brain metastases in ALK-positive NSCLC-time to adjust current treatment algorithms. Oncotarget. 2018;9(80):35181–35184.
   PubMedGoogle Scholar
• Rw S, Li W, Schinkel AH, et al. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. J Pharm Biomed Anal. 2018;161:136–143.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res. 2017;117:343–346.
   PubMed Web of Science ®Google Scholar
• Sharma GG, Mota I, Mologni L, et al. Tumor resistance against ALK targeted therapy-where it comes from and where it goes. Cancers (Basel). 2018;10(3):pii: E62.
   Web of Science ®Google Scholar
• Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881–1888.
   PubMed Web of Science ®Google Scholar
• Goyal S, Jamal S, Shanker A, et al. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase. J Cell Biochem. 2019;120(1):768–777.
   PubMed Web of Science ®Google Scholar
• Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opin Emerg Drugs. 2018;23(3):231–241.
   PubMed Web of Science ®Google Scholar
• U.S.Food and Drug Administration. LORBRENA® (lorlatinib) tablets, for oral use. [cited 2018 Nov 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf
   Google Scholar
• Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zheng J, Zhang X, et al. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment. BMC Cancer. 2018;18(1):10.
   PubMedGoogle Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):ra17.
   Web of Science ®Google Scholar
• Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016;34(24):2858–2865.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662–663.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Clark M. Ceritinib:firstglobal approval. Drugs. 2014;74(11):1285–1291.
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–919.
   PubMed Web of Science ®Google Scholar
• Nishio M, Nakagawa K, Mitsudomi T, et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2018;121:37–40.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. New Engl J Med. 2017;377(9):829–838.
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer(J-ALEX): anopenlabel,randomised phase 3 trial. Lancet. 2017;390(10089):29–39.
   PubMed Web of Science ®Google Scholar
• Markham A. Brigatinib: first global approval. Drugs. 2017;77(10):1131–1135.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Mj A, et al. Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer. N Engl J Med. 2018;379(21):2027–2029.
   PubMed Web of Science ®Google Scholar
• Huang H. Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: a catalytic receptor with many faces. Int J Mol Sci. 2018;19(11):pii, E3448.
   Web of Science ®Google Scholar
• Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials. Curr Oncol. 2018;25(Suppl 1):S59–S57.
   PubMedGoogle Scholar
• Chin LP, Soo RA, Soong R, et al. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7(11):1625–1630.
   PubMed Web of Science ®Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–4724.
   PubMed Web of Science ®Google Scholar
• Redaelli S, Ceccon M, Zappa M, et al. Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer. Cancer Res. 2018;78(24):6866–6880.
   PubMed Web of Science ®Google Scholar
• Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–71.
   PubMed Web of Science ®Google Scholar
• Hy Z, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA. 2015;112(11):3493–3498.
   PubMed Web of Science ®Google Scholar
• Basit S, Ashraf Z, Lee K, et al. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib. Eur J Med Chem. 2017;134:348–356.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label,single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drug Trials Snapshots:LORBRENA. [cited 2018 Nov 16]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ucm625520.htm
   Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1657.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study of lorlatinib in advanced ALK and ROS1 rearranged lung cancer with CNS metastasis in the absence of measurable extracranial lesions. [cited 2018 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02927340?term=Lorlatinib&rank=5. 37.ClinicalTrials.gov.PF-06463922 for crizotinib pretreated ROS1
   Google Scholar
• ClinicalTrials.gov. PF-06463922forcrizotinibpretreatedROS1 positive non-small-cell lung cancer (PFROST). [cited 2018 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03439215?term=Lorlatinib&rank=9.
   Google Scholar
• ClinicalTrials.gov. A study of lorlatinib versus crizotinib in first line treatment of patients with ALK-positive NSCLC. [cited 2018 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03052608?term=Lorlatinib&rank=4
   Google Scholar
• Addeo A, Metro G. First-line alectinib for ALK-positive lung cancer: is there room for further improvement? Drugs Context. 2018;7:212537.
   PubMedGoogle Scholar
• Millett RL, Elkon JM, Tabbara IA. Directed therapies in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Anticancer Res. 2018;38(9):4969–4975.
   PubMed Web of Science ®Google Scholar